MAP2K7 and neoplasm: MEK inhibition has been shown to protect tumor-specific effector T-cells against chronic TCR-driven apoptosis [7], increase the extent of tumor T-cell infiltration [7–9], enhance expression of tumor antigens [8, 9, 11, 12] and MHC class I on tumors [7–10, 13, 14], and reduce the accumulation of monocytic myeloid-derived suppressor cells (mMDSC) in the tumor [15].